Contrast-enhanced MR angiography: does a higher relaxivity MR contrast agent permit a reduction of the dose...

Area of Science:

• Radiology
• Vascular Imaging
• Medical Contrast Agents

Background:

• Steno-occlusive vascular disease requires accurate diagnostic imaging.
• Contrast-enhanced magnetic resonance angiography (CE-MRA) is a key tool for evaluating such conditions.
• Optimizing contrast agent dosage is crucial for balancing diagnostic efficacy and patient safety.

Purpose of the Study:

• To prospectively compare the efficacy of a single dose of gadobenate dimeglumine with a double dose of gadopentetate dimeglumine for CE-MRA.
• To evaluate these agents in patients with suspected or known steno-occlusive disease in the carotid, renal, or peripheral vasculature.
• To assess diagnostic performance and image quality using an intra-individual crossover design.

Main Methods:

• Twenty-eight patients with suspected or known steno-occlusive disease underwent two identical CE-MRA procedures in a crossover design.
• Patients received either 0.1 mmol/kg gadobenate dimeglumine or 0.2 mmol/kg gadopentetate dimeglumine in a randomized order.
• Images were assessed by blinded readers for anatomical delineation, disease detection, and preference. Diagnostic performance was compared against digital subtraction angiography (DSA).

Main Results:

• No significant differences were found in qualitative image parameters or diagnostic preference endpoints between the two contrast agents.
• Gadobenate dimeglumine demonstrated superior sensitivity for disease detection compared to gadopentetate dimeglumine (80.8-86.5% vs. 75.0-82.7%).
• Quantitative enhancement (SNR and CNR) was comparable between single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine.

Conclusions:

• A single 0.1 mmol/kg dose of gadobenate dimeglumine is a viable alternative to a double 0.2 mmol/kg dose of gadopentetate dimeglumine for routine CE-MRA.
• This substitution can be made under identical examination conditions without compromising diagnostic quality.
• The findings support the use of a lower dose of gadobenate dimeglumine, potentially improving cost-effectiveness and reducing contrast agent administration.